FOLFOXIRI plus bevacizumab as standard of care for first-line treatment in patients with advanced colon cancer

被引：2
|
作者：
Cervantes, A. [1 ]
Prager, G. W. [2 ]
机构：
[1] Univ Valencia, Hosp Clin Univ, Biomed Res Inst, Dept Med Oncol,INCLIVA, Valencia, Spain
[2] Med Univ Vienna, Dept Med 1, Vienna, Austria
来源：
ESMO OPEN | 2023年 / 8卷 / 02期
关键词：
METASTATIC COLORECTAL-CANCER; OPEN-LABEL; PHASE-II; FOLFIRI; FLUOROURACIL; OXALIPLATIN; MULTICENTER; LEUCOVORIN; CETUXIMAB; SURVIVAL;
D O I：
10.1016/j.esmoop.2023.100883
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Should FOLFOXIRI Plus Bevacizumab Be the Standard First-Line Therapy in Metastatic Colorectal Cancer?
    Nipp, Ryan D.
    Ryan, David P.
    [J]. ONCOLOGIST, 2015, 20 (03): : 236 - 238
  • [2] FOLFOXIRI PLUS BEVACIZUMAB AS FIRST-LINE TREATMENT OF BRAF MUTANT METASTATIC COLORECTAL CANCER PATIENTS
    Salvatore, Lisa
    Loupakis, Fotios
    Cremolini, Chiara
    Schirripa, Marta
    Masi, Gianluca
    Antoniotti, Carlotta
    Fornaro, Lorenzo
    Sensi, Elisa
    Lupi, Cristiana
    Bergamo, Francesca
    Lonardi, Sara
    Zagonel, Vittorina
    Fontanini, Gabriella
    Falcone, Alfredo
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 93 - 93
  • [3] FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer
    Loupakis, F.
    Cremolini, C.
    Salvatore, L.
    Masi, G.
    Sensi, E.
    Schirripa, M.
    Michelucci, A.
    Pfanner, E.
    Brunetti, I.
    Lupi, C.
    Antoniotti, C.
    Bergamo, F.
    Lonardi, S.
    Zagonel, V.
    Simi, P.
    Fontanini, G.
    Falcone, A.
    [J]. EUROPEAN JOURNAL OF CANCER, 2014, 50 (01) : 57 - 63
  • [4] FOLFOXIRI plus bevacizumab as first-line treatment of BRAF-mutant metastatic colorectal cancer patients
    Salvatore, Lisa
    Loupakis, Fotios
    Cremolini, Chiara
    Schirripa, Marta
    Masi, Gianluca
    Antoniotti, Carlotta
    Fornaro, Lorenzo
    Sensi, Elisa
    Lupi, Cristiana
    Bergamo, Francesca
    Lonardi, Sara
    Zagonel, Vittorina
    Fontanini, Gabriella
    Falcone, Alfredo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [5] Optimal Use of FOLFOXIRI Plus Bevacizumab as First-Line Systemic Treatment in Metastatic Colorectal Cancer
    Khatib, Jude
    Kainthla, Radhika
    [J]. CURRENT COLORECTAL CANCER REPORTS, 2020, 16 (04) : 89 - 95
  • [6] Bevacizumab in the First-line Treatment of advanced Ovarian Cancer
    Mallmann, Michael R.
    Alakus, Hakan
    Mallmann, Peter
    Bruns, Christiane
    [J]. ONKOLOGE, 2019, 25 (11): : 1020 - 1021
  • [7] First-line bevacizumab for ovarian cancer—new standard of care?
    Susana Banerjee
    Stan B. Kaye
    [J]. Nature Reviews Clinical Oncology, 2012, 9 : 194 - 196
  • [8] Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial
    Cremolini, Chiara
    Malmorino, Federica
    Bergamo, Francesca
    Aprile, Giuseppe
    Salvatore, Lisa
    Masi, Gianluca
    Dell'Aquila, Emanuela
    Antoniotti, Carlotta
    Murgioni, Sabina
    Allegrini, Giacomo
    Borelli, Beatrice
    Gemma, Donatello
    Casagrande, Mariaelena
    Granetto, Cristina
    Delfanti, Sara
    Di Donato, Samantha
    Schirripa, Marta
    Sensi, Elisa
    Tonini, Giuseppe
    Lonardi, Sara
    Fontanini, Gabriella
    Boni, Luca
    Falcone, Alfredo
    [J]. EUROPEAN JOURNAL OF CANCER, 2019, 109 : 175 - 182
  • [9] Advanced hepatocellular Carcinoma Atezolizumab plus Bevacizumab - new First-Line Therapy Standard
    Vetter, Christine
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 (7-8) : 429 - 429
  • [10] REINTRODUCTION OF FOLFOXIRI TREATMENT IN METASTATIC COLORECTAL CANCER PATIENTS PROGRESSED AFTER FIRST-LINE FOLFOXIRI
    Baldi, Giacomo Giulio
    Vasile, Enrico
    Masi, Gianluca
    Loupakis, Fotios
    Stasi, Irene
    Salvatore, Lisa
    Fornaro, Lorenzo
    Cupini, Samanta
    Pfanner, Elisabetta
    Brunetti, Isa Maura
    Di Donato, Samantha
    Caponi, Sara
    Allegrini, Giacomo
    Antonuzzo, Andrea
    Ricci, Sergio
    Andreuccetti, Michele
    Falcone, Alfredo
    [J]. ANNALS OF ONCOLOGY, 2009, 20
12345